Nuclear medicine procedures in the diagnosis of NET: a historical perspective.
Novel diagnostic tools and therapies have emerged as a result of the continuous endeavors relating to neuroendocrine tumors (NETs). Nuclear medicine plays a pivotal role in the imaging and treatment of NETs. Somatostatin receptor analogues and metaiodobenzylguanidine remain front-line single-photon emission computed tomography (SPECT) radiotracers in the imaging of NET; their utility has been augmented by the increasing availability of SPECT/CT. Positron emission tomography has been growing rapidly in the imaging of NETs, paralleled by great efforts toward the development of new tracers. Hybrid imaging will play an important role in the future of NETs.